Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma

QR Code

Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma

Background and aimsMost Hepatocellular carcinoma (HCC) diagnoses occur at advanced stages precluding radical surgical resections. Conversion therapy offers a viable chance for patients with unresectable HCC (uHCC) to become eligible for curative surgery. Despite the application of various treatment...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhuoran Wang, Cunzhen Zhang, Jianhua Yin, Nan Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Immunology
Subjects:	hepatocellular carcinoma TACE anti-angiogenic therapy anti-PD-1 antibody conversion therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1451965/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Correction: Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma
by: Zhuoran Wang, et al.
Published: (2025-06-01)

Comparative Effectiveness and Safety of Molecular Targeted Therapy Plus PD-(L)1 with or without TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Study
by: Liu J, et al.
Published: (2025-07-01)

Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis
by: Wei Lu, et al.
Published: (2025-06-01)

Corneal neovascularization: a modern view of molecular mechanisms and methods of therapy
by: G. S. Arzhimatova, et al.
Published: (2023-07-01)

Efficacy of therapies for intermediate-stage hepatocellular carcinoma: systematic review and network meta-analysis
by: Shaoqi Zong, et al.
Published: (2025-07-01)

PATHOPHYSIOLOGICAL REASONING OF THE EFFICIENCY OF ANTI-ANGIOGENIC THERAPY IN THE RETINAL VEIN OCCLUSION BY THE COHERENT EYE TOMOGRAPHY
by: V. Yu. Mykhaylichenko, et al.
Published: (2018-05-01)

TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study
by: Lu C, et al.
Published: (2025-07-01)

Primary hepatic squamous cell carcinoma with pseudoachalasia treated with TACE: Case report and literature review
by: Yang He, MM, et al.
Published: (2025-10-01)

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bi-specific antibody) and adjuvant anti-angiogenesis therapy in treated, recurrent, or metastatic cervical cancer
by: Fang Zhou, et al.
Published: (2025-06-01)

Interventional treatment combined with immunotargeted therapy in unresectable combined hepatocellular-cholangiocarcinoma: a real-world retrospective cohort study
by: Yan-Song Lin, et al.
Published: (2025-07-01)

Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report
by: Hongming Wang, et al.
Published: (2025-06-01)

Efficacy and safety of D-TACE followed by D-RFA for unresectable large hepatocellular carcinoma
by: Qingqing Pang, et al.
Published: (2025-07-01)

Heparin, Heparin-like Molecules, and Heparin Mimetics in Breast Cancer: A Concise Review
by: Diego R. Gatica Portillo, et al.
Published: (2025-07-01)

Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study
by: Chengxiang Guo, et al.
Published: (2025-02-01)

Efficacy Analysis of TACE Combined with Lenvatinib and PD-1 Inhibitors in the Treatment of Hepatitis B Virus-Related Unresectable Hepatocellular Carcinoma
by: Yu J, et al.
Published: (2025-07-01)

Efficacy and safety of TACE-HAIC combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for the patients with BCLC-defined stage B-C HCC
by: Bowen Liu, et al.
Published: (2025-07-01)

PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma
by: Jitong Zhou, et al.
Published: (2025-07-01)

Harnessing multi-omics and artificial intelligence: revolutionizing prognosis and treatment in hepatocellular carcinoma
by: Zhen Wang, et al.
Published: (2025-07-01)

Trimetallic Pt-Pd-Au alloy nanozymes for multimodal synergistic therapy to overcome deep-seated drug-resistant infections via ROS cascade
by: Xiaojun He, et al.
Published: (2025-09-01)

Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice
by: V. V. Petkau, et al.
Published: (2022-12-01)

Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR‐TKI Treatment: A Retrospective Cohort Study
by: Yi‐Tse Su, et al.
Published: (2025-07-01)

An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti‐Angiogenic Agents for Therapy: A Case Report
by: Li Wang, et al.
Published: (2025-06-01)

DCP as a biomarker for TACE efficacy in hepatocellular carcinoma
by: Hui Xie, et al.
Published: (2025-07-01)

Ischemic Stroke Post-Transradial Chemoembolization
by: Almamoon I. Justaniah, et al.
Published: (2024-01-01)

Aqeuous humor cytokines concentration changes in patients with diabetic macular edema after intravitreal pharmacotherapy
by: A. Zh. Fursova, et al.
Published: (2023-07-01)

The impact of intravitreal therapy of diabetic macular edema on the local and systemic production of cytokines
by: A. Zh. Fursova, et al.
Published: (2023-03-01)

Price Analysis of Systemic Therapies and Transarterial Radioembolization for Treatment of Unresectable Hepatocellular Carcinoma
by: Abimbola O. Williams, et al.
Published: (2025-05-01)

The Association between Peripheral Th17, Th1, IL-17, and IFN-γ Levels and TACE Response in Patients with Unresectable Hepatocellular Carcinoma with or without Cirrhosis
by: Irsan Hasan, et al.
Published: (2020-12-01)

The Association between Peripheral Th17, Th1, IL-17, and IFN-γ Levels and TACE Response in Patients with Unresectable Hepatocellular Carcinoma with or without Cirrhosis
by: Irsan Hasan, et al.
Published: (2020-12-01)

Factor Analysis of the Effect of Hepatitis B-Related Liver Cancer Treatment Efficacy
by: Liu SW, et al.
Published: (2025-06-01)

Clinical Outcomes of AFP-Negative Patients with Advanced HCC: A Propensity-Matched Analysis from a Retrospective Cohort Study
by: Liu X, et al.
Published: (2025-06-01)

Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients
by: Yirui Zhai, et al.
Published: (2025-08-01)

Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophages
by: Rongrong Zhao, et al.
Published: (2025-06-01)

Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements
by: Wei Xu, et al.
Published: (2025-05-01)

Liver Transplantation in the Treatment of Unresectable Hepatocellular Carcinoma in the Absence of Liver Cirrhosis
by: O. D. Olisov, et al.
Published: (2018-09-01)

Adjuvant Lenvatinib for High-Risk CNLC IIb/IIIa Hepatocellular Carcinoma After Curative Hepatectomy: A Prospective Exploratory Study
by: Sun HC, et al.
Published: (2025-05-01)

Research Progress of Immune Checkpoint Inhibitors Combined with Anti-Angiogenic Drugs in Treatment of Advanced Non-Small Cell Lung Cancer
by: Aiju ZENG, et al.
Published: (2025-06-01)

Current Status and Future of Multidisciplinary Team in Hepatocellular Carcinoma
by: Jinbin CHEN, et al.
Published: (2025-06-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

Features of vasoactive substance regulation in chorionic villi in women with spontaneous abortion and active cytomegalovirus infection
by: I. A. Andrievskaya, et al.
Published: (2022-07-01)